Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

95.15 -1.95 (-2.01%)

Streaming Delayed Price Updated: 12:16 PM EDT, Apr 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

26 27 Next >

These S&P500 stocks are moving in today's pre-market session ↗

March 07, 2025

The US market session of Friday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

March 03, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

What's going on in today's session: S&P500 gap up and gap down stocks ↗

March 03, 2025

Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

February 28, 2025

From Incyte

Via Business Wire

What Analysts Are Saying About Incyte Stock ↗

February 11, 2025

Via Benzinga

Insights into Incyte Q4 Earnings ↗

February 10, 2025

Via Benzinga

NASDAQ:INCY, an undervalued stock with good fundamentals. ↗

December 26, 2024

INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

February 20, 2025

From Genesis Therapeutics, Inc. and Incyte

Via Business Wire

NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

February 18, 2025

Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.

Via Chartmill

Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect

February 18, 2025

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Incyte to Present at Upcoming Investor Conferences

February 18, 2025

From Incyte

Via Business Wire

The Analyst Verdict: Incyte In The Eyes Of 15 Experts ↗

December 19, 2024

Via Benzinga

What's going on in today's pre-market session: S&P500 movers ↗

February 11, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

Why Incyte (INCY) Shares Are Plunging Today

February 10, 2025

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products such as...

Via StockStory

Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday? ↗

February 10, 2025

Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while...

Via Benzinga

Topics Government World Trade

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 10, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Gapping S&P500 stocks in Monday's session ↗

February 10, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches ↗

February 10, 2025

Incyte projects 2025 Jakafi revenue of $2.925B-$2.975B, up 4.76%-6.55%, and Opzelura sales of $630M-$670M, reflecting up to 31.81% growth.

Via Benzinga

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4

February 10, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per share...

Via StockStory

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

February 10, 2025

From Incyte

Via Business Wire

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

February 09, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.

Via StockStory

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 07, 2025

From Incyte

Via Business Wire

Promising Signs: INCYTE CORP Setting the Stage for a Breakout. ↗

February 05, 2025

Exploring INCYTE CORP's Technical Signals and Breakout Potential: Based on good technical signals, INCYTE CORP is potentially setting up for a breakout.

Via Chartmill

Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents. ↗

January 24, 2025

Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.

Via Chartmill

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

January 21, 2025

From Incyte

Via Business Wire

Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline ↗

January 14, 2025

Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.

Via Benzinga

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 08, 2025

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

December 17, 2024

From Incyte

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.